First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer

Overview of attention for article published in The Breast, June 2017

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 20 Dimensions

Readers on

mendeley: 80 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 20 publications that cite this research output.

20

The most recent citing publications are shown below. View all 20 publications that cite this research output on Dimensions.

From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds

Article in Frontiers in Pharmacology (September 2022)

Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS)

Article in Cancer Science (July 2022)

Prognostic importance of peripheral blood parameters in HER-2 positive metastatic breast cancer treated by pertuzumab, trastuzumab and docetaxel

Article in Medical Science and Discovery (December 2021)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.